April 13-14, 2005
MedChem Europe
Berlin Germany
www.medchemeurope.com

May 10-12, 2005
PharmaDiscovery 2005
Convention Center Washington, D.C.
www.pharmadiscovery2005.com

May 18-20, 2005
Bio-Collaborations Asia
Boston Park Plaza Hotel
Boston, MA
www.ibclifesciences.com/3109

June 1-3, 2005
Drug Discovery & Development Asia-Pacific
Shangri-La Hotel
Singapore
www.drugdisc.com/3110
 

All News | Meetings | Submit News / Press Release New Products

04/27/04
Mount Sinai School of Medicine researchers have discovered how the membrane protein that allows us to sense cold works and how this protein becomes desensitized so that one no longer feels cold.
The study, published this week as an advance online publication by Nature Neuroscience, focused on a specific region of the cold receptor which is found in many other receptors, including ones involved in taste, vision and fertilization. Therefore, the findings may have important implications across a wide range of areas.
Source: Bio.com

4/27/2005
GPC Biotech and Ingenium receive joint drug discovery grant.    US-based GPC Biotech will share a grant with Germany's Ingenium Pharmaceuticals for $2.8 million. The grant, donated by the German Ministry for Education and Research, will ensure each company receives $1.4 million every year until 2007  The collaboration sees both companies working towards establishing proof of concept for the activity of specific kinase inhibitors using animal models, and will cover several disease areas.
Source: Business Wire

4/25/2005
Oxford Instruments Molecular Biotools Ltd Presents Hypersense™ For Ultra-High NMR Sensitivity Enhancement.  HyperSense™ has a potential to revolutionise the field of Nuclear Magnetic Resonance (NMR) spectroscopy. HyperSense™ is a groundbreaking in vitro DNP polarizer capable of amplifying the baseline sensitivity of NMR systems by a factor of up to 104. This instrument will be the first commercial product of its kind.
Source:BioResearch Online

04/18/2005
BioGenex announces the launch of the Xmatrx, a walk-away system that automates molecular diagnostics and drug target identification and validation.  BioGenex, the pioneer of integrated, industrial-scale, high throughput automation for molecular pathology, announced at the 2005 annual meeting of the American Association for Cancer Research (AACR) the launch of Xmatrx(TM), a revolutionary walk-away system for cell and tissue staining applications, for use in drug research and development.
Source: RedNova

4/11/2005
Trigen Holdings plc and ProCorde GmbH announced today that they have merged their interests into Trigen Holdings AG. The combination of Trigen and ProCorde creates a leader in cardiovascular drug discovery and development, focussing on thrombosis and vascular dysfunction.
Source: Business Wire

4/08/2005
Innovadyne Technologies, Inc has been granted US patent number 6,852,291, "Hybrid Valve Apparatus and Method for Fluid Handling". Novel design ensures the isolation of disoense actuators from reagents and samples, significantly increasing reliability and performace. 
Source: Innovadyne Technologies

4/06/2005
Invitrogen Signs Broad Kinase Screening Agreement with Plexxikon. Invitrogen Corporation, a provider of essential life science technologies for disease research and drug discovery, announced that Plexxikon Inc. has contracted Invitrogen to provide kinase screening services in order to rapidly exploit Plexxikon proprietary kinase inhibitor libraries for the development of novel drug candidates in oncology, inflammation and other diseases.
Source: Business Wire

4/04/2005
Expansion of High Content Screening Capabilities at the National Center for Drug Screening in China.  NCDS, Shanghai, China and Cellomics, Inc. of Pittsburgh, Pennsylvania, U.S.A. announced an addition to their strategic collaboration aimed at expanding the application of High Content Screening (HCS) technologies in China. Affiliated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, the Center is a key national technology innovation base in drug discovery and development.  Cellomics, Inc is recognized as the creator of and market leader in HCS, providing a unique cell-based platform to its global clients in pharmaceutical, biotechnology and academic institutions.
Source: Business Wire

3/23/2005
Pharmacopeia and CV Therapeutics Announce Drug Discovery and Development Collaboration.
Pharmacopeia is employing its comprehensive, integrated drug discovery platform and discovery expertise that has, to date, resulted in four programs advancing into human clinical trials with its partners.  CV Therapeutics will be responsible for development and marketing of collaboration products, and will bring its substantial pharmacology and clinical expertise and experience to the collaboration.
Source: Business Wire

3/22/2005
Duke Comprehensive Cancer Center scientists have discovered a potential new drug that inhibits destructive cell signals that drive the growth of one-third of all cancers. The scientists showed they could block the growth of cultured colon cancer cells using this new compound, called cysmethynil.
Source: Bio.com